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AbstrACt
Objectives SB4 (Benepali, Brenzys) is a biosimilar of 
reference etanercept (Etn). In a randomised, double-
blind, 52-week study, SB4 demonstrated comparable 
efficacy and safety to Etn in patients with rheumatoid 
arthritis (rA). the open-label extension period evaluated 
long-term efficacy, safety and immunogenicity when 
continuing SB4 versus switching from Etn to SB4.
Methods In the randomised, double-blind phase, 
patients received weekly subcutaneous administration 
of 50 mg SB4 or Etn with background methotrexate 
for up to 52 weeks. patients in the Czech republic and 
poland who completed the 52-week visit were enrolled 
in the open-label extension period and received SB4 for 
48 additional weeks. Efficacy, safety and immunogenicity 
were assessed up to week 100.
results of 245 patients entering the extension 
period, 126 continued to receive SB4 (SB4/SB4) and 
119 switched to SB4 (Etn/SB4). American College of 
rheumatology (ACr) response rates were sustained and 
comparable between SB4/SB4 and Etn/SB4 with ACr20 
response rates at week 100 of 77.9% and 79.1%, 
respectively. other efficacy results, including radiographic 
progression, were also comparable between the groups. 
After week 52, rates of treatment-emergent adverse 
events were 47.6% (SB4/SB4) and 48.7% (Etn/SB4); 
one patient/group developed non-neutralising antidrug 
antibodies. no cases of active tuberculosis or injection-
site reactions were reported during the extension period. 
one patient (SB4/SB4) died of hepatic cancer.
Conclusions SB4 was effective and well tolerated 
over 2 years in patients with rA. Efficacy, safety and 
immunogenicity were comparable between the SB4/SB4 
and Etn/SB4 groups, showing no risk associated with 
switching patients from Etn to SB4.
trial registration number nCt01895309; 2012-
005026-30
IntrOduCtIOn
The tumour necrosis factor inhibitor etanercept was 
the first approved biologic disease-modifying anti-
rheumatic drug and allowed for a major advance in 
the treatment of rheumatoid arthritis (RA).1 Eigh-
teen years since its approval, etanercept continues to 
play a key role in RA management, having demon-
strated efficacy and a manageable safety profile in 
both clinical trial and real-world settings.1 Other 
current indications for etanercept include juvenile 
idiopathic arthritis, psoriatic arthritis, ankylosing 
spondylitis, non-radiographic axial spondyloar-
thritis (European Union only), plaque psoriasis and 
paediatric psoriasis (USA only).2 3
SB4 (Benepali, Samsung Bioepis UK Limited, 
Surrey, UK; Brenzys, Samsung Bioepis, Republic 
of Korea) is a biosimilar of reference etanercept 
(ETN). The structural, physicochemical and biolog-
ical quality attributes of SB4 have been shown to be 
highly similar to ETN in a comprehensive compa-
rability exercise designed as part of the European 
Medicines Agency’s rigorous approval pathway.4 
A phase 1 study in healthy subjects demonstrated 
pharmacokinetic equivalence between SB4 and 
ETN5 ; a phase 3 study (NCT01895309; EudraCT 
2012-005026-30) in patients with moderate to 
severe RA despite treatment with methotrexate 
(MTX) demonstrated equivalent efficacy in terms 
of American College of Rheumatology 20% 
response rate (ACR20) at the 24-week interim anal-
ysis (SB4, 78.1%; ETN, 80.3%)6 and at week 52 
(SB4, 80.8%; ETN, 81.5%).7 Safety was generally 
comparable between SB4 and ETN.6 7
SB4 has been approved for treatment of RA, 
psoriatic arthritis, ankylosing spondylitis, non-ra-
diographic axial spondyloarthritis and plaque 
psoriasis in the European Union.8 9 However, an 
important consideration for prescribing physicians 
is whether switching from ETN to SB4, which may 
occur in clinical practice, can be achieved without 
detriment to safety and efficacy. We analysed data 
from the open-label extension period of the phase 3 
study to evaluate the efficacy, safety and immunoge-
nicity of continuing SB4 (SB4/SB4) versus switching 
from ETN to SB4 (ETN/SB4). Long-term safety and 
efficacy were assessed up to week 100.
MethOds
study design and patients
Patients with moderate to severe RA despite treat-
ment with MTX were eligible to enrol in this phase 
3, randomised, double-blind, multicentre study, 
which included an open-label extension period. 
Detailed patient inclusion/exclusion criteria were 
previously published.6 During the double-blind 
period, patients were randomised 1:1 to receive 
subcutaneous SB4 50 mg or ETN 50 mg once 
weekly for 52 weeks. Patients in the Czech Republic 
or Poland who completed the scheduled 52-week 
visit were enrolled in the open-label, single-arm 
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extension period. During the extension period, patients from 
the SB4 group continued to receive SB4 (SB4/SB4), and patients 
from the ETN group switched to SB4 50 mg (ETN/SB4) once 
weekly for an additional 48 weeks. All patients took a stable 
dose of MTX (10–25 mg/week) from 4 weeks before screening 
until the end-of-treatment visit for the extension period. For 
patients who entered the extension period, efficacy was assessed 
at weeks 52, 76 and 100, and safety was assessed at all visits 
during treatment and at 4 weeks after treatment (or after the 
early termination visit).
endpoints
Efficacy endpoints for the extension period included 
ACR20/50/70 response (≥20%/50%/70% improvement, respec-
tively, from baseline in ACR response criteria), European League 
Against Rheumatism (EULAR) response and disease activity 
score based on a 28-joint count (DAS28). Physical function 
was assessed using the Health Assessment Questionnaire-Dis-
ability Index (HAQ-DI). For patients who entered the extension 
period, radiographs of the hands and feet obtained at weeks 
0, 52 and 100 were evaluated by a single reader to determine 
the modified Total Sharp Score (mTSS), which is the sum of 
the joint erosion and joint space narrowing (JSN) scores.10 Post 
hoc assessments included the proportions of patients achieving 
low disease activity (LDA) and remission based on the Simpli-
fied Disease Activity Index (SDAI), Clinical Disease Activity 
Index (CDAI) and DAS28 and the proportions achieving Bool-
ean-based remission (defined as ≤1 swollen and ≤1 tender joint, 
C-reactive protein ≤1 mg/dL and patient global visual analogue 
scale score ≤1 using a 0–10 scale). Safety endpoints included 
the incidence of treatment-emergent adverse events (TEAEs) 
and adverse events (AEs) of special interest (serious infections 
and active tuberculosis). Immunogenicity was assessed by deter-
mining the incidence of antidrug antibodies (ADAs) and neutral-
ising antibodies; ADAs were detected in serum samples using an 
electrochemiluminescence bridging assay (Meso Scale Discovery, 
Maryland, USA), double-antigen format with acid dissociation 
and neutralising antibodies were measured using a competitive 
ligand-binding assay.6
statistical analysis
All data were analysed descriptively. Efficacy and safety data 
were analysed in the extended population, which comprised 
all patients who provided informed consent for the open-label 
extension period and received ≥1 dose of study medication in 
the open-label extension period. Efficacy data obtained up to 
week 52 were analysed retrospectively in this population. No 
imputation was made for missing data. Analyses were performed 




A total of 245 patients, including 126 who continued on SB4 
and 119 who switched to SB4 from ETN, enrolled in the exten-
sion period. All patients received ≥1 dose of study drug during 
the extension period and were included in this analysis. Patient 
disposition is shown in figure 1; 94.7% of patients (232/245) 
who entered the extension period completed 100 weeks of treat-
ment, with 5.6% of patients in the SB4/SB4 group and 5.0% 
of patients in the ETN/SB4 group withdrawing before week 
100. Patient demographic and clinical characteristics were well 
balanced between the two groups (table 1).
efficacy
ACR responses were comparable between the SB4/SB4 and ETN/
SB4 groups and were maintained from weeks 52 through 100, 
with 79.2%/52.0%/38.4% and 82.4%/53.8%/32.8% of patients 
achieving ACR20/50/70 in each group, respectively, at week 52% 
Figure 1 Patient disposition. AE, adverse event; ETN, reference etanercept.
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and 77.9%/59.8%/42.6% and 79.1%/60.9%/41.7% of patients 
achieving ACR20/50/70 in each group, respectively, at week 
100 (figure 2). ACR responses were also comparable between 
the two groups in the retrospective analysis of this population 
during the initial 52-week treatment period. Other efficacy 
results at week 100 are shown in table 2. At this time point, 
the proportion of patients who had moderate or good EULAR 
responses; the proportion who achieved LDA and remission 
based on DAS28, SDAI or CDAI criteria and the proportion who 
achieved Boolean-based remission were comparable between the 
SB4/SB4 and ETN/SB4 groups. Further, throughout the study, 
DAS28, SDAI, CDAI and HAQ-DI scores were also comparable 
between the two groups (see figure in the online supplementary 
material 1). The main factor driving the improvement in DAS28 
score was the reduction in swollen and tender joint counts; these 
components demonstrated the largest percentage improvements 
from baseline during the extension period. At week 100, radio-
graphic progression was comparable and minimal (figure 3), with 
mean (SD) change from baseline mTSS values of 0.48 (4.053) for 
the SB4/SB4 group and 1.00 (5.563) for the ETN/SB4 group 
(table 2). Summary of structural joint damage for each visit can 
be found in table S1 in the online supplementary material 1.
safety
Safety after week 52 was generally comparable between the SB4/
SB4 and ETN/SB4 groups (table 3). This extension study was 
not adequately powered to showsimilar safety and imbalance 
might be expected as shown in the incidence of serious TEAEs, 
RA, viral infection, laryngitis and hypertension. Serious infection 
was reported in one patient in each treatment group, and there 
were no reports of active tuberculosis. Also during the extension 
period, no injection-site reactions were reported. One patient in 
the SB4/SB4 group died of hepatic cancer, which was considered 
to be related to the study drug. One patient in each treatment 
group developed non-neutralising ADAs after week 52 (see table 
S2 in the online supplementary material 1). Both patients had a 
low titre, and the ADAs did not affect efficacy. The patient in the 
SB4/SB4 group tested positive at week 100 with a titre of 1 and 
achieved an ACR50 response at week 100. The patient from the 
ETN/SB4 group tested positive at week 76 with a titre of <1 and 
achieved an ACR70 response at week 100.
dIsCussIOn
This open-label extension period of a phase 3, randomised, 
double-blind study evaluated the long-term efficacy, safety and 
immunogenicity of SB4 in patients with moderate to severe 
RA despite MTX treatment and compared outcomes between 
patients who continued SB4 (n=126) and those who switched 
from ETN to SB4 (n=119). Results showed SB4 to be effective 
table 1 Patient baseline demographics and disease characteristics 






Age, years 49.9 (12.05) 52.1 (10.91)
Women, n (%) 107 (84.9) 100 (84.0)
White, n (%) 126 (100.0) 118 (99.2)
BMI, kg/m2 26.7 (5.80) 26.1 (5.05)
Disease duration, years 5.7 (3.94) 5.8 (4.18)
Duration of MTX use, months 46.0 (35.63) 43.9 (39.81)
Weekly dose of MTX, mg 16.9 (4.92) 16.5 (4.91)
Swollen joint count (0–66)
  Baseline 14.4 (7.25) 14.4 (7.74)
  Week 52 2.9 (4.84) 2.8 (4.30)
Tender joint count (0–68)
  Baseline 21.0 (9.96) 21.4 (11.08)
  Week 52 5.0 (7.11) 5.6 (7.86)
Physician VAS (0–100)
  Baseline 62.4 (16.35) 63.6 (15.25)
  Week 52 16.8 (14.47) 18.8 (15.27)
Patient VAS (0–100)
  Baseline 58.9 (19.75) 61.5 (18.08)
  Week 52 24.9 (20.97) 26.8 (19.62)
Patient pain VAS (0–100)
  Baseline 59.0 (21.38) 60.5 (20.22)
  Week 52 25.8 (21.86) 27.0 (21.32)
HAQ-DI (0–3)
  Baseline 1.38 (0.555) 1.45 (0.597)
  Week 52 0.68 (0.585) 0.74 (0.651)
DAS28
  Baseline 6.22 (0.908) 6.26 (0.877)
  Week 52 3.40 (1.179) 3.49 (1.119)
SDAI
  Baseline 37.01 (12.037) 37.65 (12.052)
  Week 52 10.04 (8.589) 10.38 (8.713)
CDAI
  Baseline 35.85 (11.586) 36.45 (11.672)
  Week 52 9.41 (8.249) 10.01 (8.670)
CRP, mg/L
  Baseline 11.5 (15.71) 12.0 (16.35)
  Week 52 6.2 (15.84) 3.8 (5.47)
ESR, mm/h
  Baseline 41.9 (23.26) 41.7 (19.53)
  Week 52 24.5 (18.63) 22.2 (16.21)
Rheumatoid factor positive, n (%) 99 (78.6) 89 (74.8)
Values represent mean (SD) unless otherwise specified.
BMI, body mass index; CDAI, Clinical Disease Activity Index; CRP, C-reactive 
protein; DAS28, disease activity score based on a 28-joint count; ESR, 
erythrocyte sedimentation rate; ETN, reference etanercept; HAQ-DI, Health 
Assessment Questionnaire-Disability Index; MTX, methotrexate; SDAI, Simplified 
Disease Activity Index; VAS, visual analogue scale.
Figure 2 American College of Rheumatology (ACR) response rates 
up to week 100 (extended population). ACR20/50/70=American 
College of Rheumatology 20%/50%/70% response criteria; 
ETN, reference etanercept.
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and well tolerated over 2 years. In patients who switched from 
ETN to SB4, comparable efficacy to the SB4/SB4 group was 
observed, with no new safety signals identified.
Among the patients entering the extension period, 94.4% in 
the SB4/SB4 group and 95.0% in the ETN/SB4 group completed 
an additional 48 weeks of SB4 treatment. The discontinua-
tion rate due to lack of efficacy or TEAEs was very low, which 
suggests the long-term tolerability of SB4 treatment.
Efficacy outcomes in the extended population were compa-
rable between the SB4/SB4 and ETN/SB4 groups at all visits up 
to week 100, sustained from weeks 52 to 100 and unaffected by 
switching. Comparable inhibition of radiographic progression 
was previously reported after 52 weeks of treatment with SB4 or 
ETN (mean change in mTSS: 0.45 for SB4 vs 0.74 for ETN).7 In 
both groups, continued inhibition of radiographic progression was 
observed with an additional year of SB4 treatment, with mean 
changes from baseline in joint space narrowing and joint erosion 
of <1. This is consistent with historical results from randomised 
studies of etanercept with or without MTX in patients with 
RA.11–13 Two-year radiographic findings in patients with early 
RA continuing ETN+MTX therapy from year 1 showed a mean 
Sharp/van der Heijde score change of −0.02 and an improvement 
in mean 28-swollen joint count from 1.7 to 1.3.11 Similarly, 2-year 
data from the Canadian Methotrexate and Etanercept Outcome 
study showed that patients continuing ETN+MTX therapy after 
the first 6 months had mean changes from baseline in mTSS and 
JSN of 0.0 at month 24 and those switching to ETN monotherapy 
had mean changes from baseline in mTSS and JSN of <1.12 Lastly, 
the Trial of Etanercept and Methotrexate with Radiographic Patient 
Outcomes (TEMPO) demonstrated mean changes from baseline in 
mTSS, joint erosion scores and JSN of <1 at years, 1, 2 and 3 of 
treatment with ETN+MTX.13
In the extension period, SB4 demonstrated a safety profile 
similar to that observed in the pivotal etanercept trials.11–13 There 
were no reports of active tuberculosis or injection-site reactions. 
One patient in each group reported a serious infection and one 





EULAR response, n/N* (%)
  Good 59/121 (48.8) 63/115 (54.8)
  Moderate 54/121 (44.6) 40/115 (34.8)
  No response 8/121 (6.6) 12/115 (10.4)
DAS28
  Improvement from baseline, mean (SD) 2.9 (1.5) 3.0 (1.5)
  Disease activity, n/N* (%)
  Low (≤3.2) 60/122 (49.2) 63/115 (54.8)
  Remission (<2.6) 37/122 (30.3) 40/115 (34.8)
SDAI score
  Improvement from baseline, mean (SD) 27.4 (15.5) 28.7 (14.6)
  Disease activity, n/N* (%)
  Low (>3.3 and≤11) 41/123 (33.3) 44/115 (38.3)
  Remission (≤3.3) 38/123 (30.9) 39/115 (33.9)
CDAI score
  Improvement from baseline, mean (SD) 26.8 (15.0) 27.9 (14.1)
  Disease activity, n/N* (%)
  Low (>2.8 and≤10) 38/123 (30.9) 46/115 (40.0)
  Remission (≤2.8) 40/123 (32.5) 33/115 (28.7)
Boolean-based remission, n/N* (%) 31/123 (25.2) 23/115 (20.0)
Radiographic results†
  Change from baseline in JSN score, 
mean (SD)
0.19 (1.98) 0.39 (2.86)
  Change from baseline in joint erosion 
score, mean (SD)
0.28 (2.57) 0.61 (3.08)
  Change from baseline in mTSS, mean 
(SD)
0.48 (4.05) 1.0 (5.56)
*Number of patients with available data at each time point.
†Based on number of patients who completed week 100 visit with available 
radiographic assessment results at weeks 0 and 100 (SB4/SB4, n=108; ETN/SB4, 
n=104).
CDAI, Clinical Disease Activity Index; DAS28, disease activity score based on 
a 28-joint count; ETN, reference etanercept; EULAR, European League Against 
Rheumatism; JSN, joint space narrowing; mTSS, modified Total Sharp Score; SDAI, 
Simplified Disease Activity Index.
Figure 3 Cumulative probability of mTSS change from baseline at 
week 100 (extended population). Data based on patients with available 
radiographic assessment results at each visit. ETN, reference etanercept; 
mTSS, modified Total Sharp Score.






≥1 TEAE 60 (47.6) 58 (48.7)
Frequently reported TEAEs 
(≥3%)
  Upper respiratory tract 
infection
10 (7.9) 9 (7.6)
  Pharyngitis 9 (7.1) 5 (4.2)
  Rheumatoid arthritis 7 (5.6) 3 (2.5)
  Bronchitis 6 (4.8) 7 (5.9)
  Nasopharyngitis 6 (4.8) 5 (4.2)
  Viral infection 4 (3.2) 1 (0.8)
  Laryngitis 4 (3.2) 0 (0.0)
  Hypertension 1 (0.8) 5 (4.2)
≥1 serious TEAE 6 (4.8) 2 (1.7)
TEAE leading to study drug 
discontinuation 4 (3.2) 2 (1.7)
Serious infection 1 (0.8) 1 (0.8)
Active tuberculosis 0 (0.0) 0 (0.0)
Injection-site reaction* 0 (0.0) 0 (0.0)
Malignancy† 1 (0.8) 0 (0.0)
Death† 1 (0.8) 0 (0.0)
*TEAE with high-level group term of administration site reaction.
†Hepatic cancer, which was considered related to study drug.
ETN, reference etanercept; TEAE, treatment emergent adverse event.
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patient in the SB4/SB4 group died from hepatic cancer. After 
week 52, one patient in each group developed non-neutralising 
ADAs. The low incidence of non-neutralising ADAs observed in 
the study was expected given the low rates reported in short-
term and long-term studies of etanercept-treated patients with 
RA (0%–6%).14–16 The ADAs developed prior to switching did 
not affect the efficacy or safety of SB4 in the ETN/SB4 group.
Results from this extended-period switching study showed 
maintenance of response after switching from ETN to SB4 with 
no newly identified safety issues (eg, no increase in immuno-
genicity or immune-related TEAEs of anaphylaxis, hypersen-
sitivity or injection-site reactions). In extensions of PLAN-
ETRA (Program evaLuating the Autoimmune Disease iNvEstiga-
tional Drug cT-p13 in RA Patients)17 and PLANETAS (Program 
evaLuating the Autoimmune Disease iNvEstigational Drug 
cT-p13 in AS patients)18 which had similar study designs with 
the present study, switching from reference infliximab to the 
biosimilar infliximab CT-P13 was not associated with dimin-
ished efficacy or change in safety profile. These results are 
further corroborated by findings from the randomised, non-infe-
riority NOR-SWITCH study which demonstrated that switching 
to CT-P13 is not inferior to continued treatment with reference 
infliximab.19 In addition, data from the DANBIO registry where 
a nationwide switch took place, disease activity was not affected 
by the non-medical switch from the reference infliximab or ETN 
to CT-P13 or SB4, respectively.20 21 Observations from these 
studies provide data relevant to clinical practice and support 
switching of reference products to biosimilars for non-medical 
reasons.
A retrospective analysis of our data was conducted for any 
potential anaphylaxis cases using related AEs (eg, pruritus, 
flushing, dyspnoea, hypotonia, syncope, incontinence, vomiting) 
and blood pressure (systolic blood pressure <90 mm Hg 
or >30% decrease from baseline), as defined in the National 
Institute of Allergy and Infectious Diseases/Food Allergy Anaphy-
laxis Network criteria.22 No cases of potential anaphylaxis were 
identified based on this analysis.
The open-label nature of the extension period is a study 
limitation. Because patients were required to have completed 
the 52-week visit of the randomised, double-blind period in 
order to enrol in the extension, there was the potential for 
selection bias. However, baseline demographic and clinical 
characteristics were well balanced between the treatment 
groups and were representative of those in the core study. 
Moreover, disease activity at week 52 for patients who enrolled 
in the extension period was comparable with that of patients 
who did not enrol in the extension period (see table S3 in 
the online supplementary material 1), suggesting no selection 
bias towards patients who responded well to treatment. This 
switching study was designed to evaluate approximately 100 
patients in each group to allow detection of an increase in 
the risk for injection site reactions to 1% or more. Therefore, 
the two countries with the largest number of enrolled patients 
(Poland and the Czech Republic) were selected to participate 
in the extension period. Although the extension period was 
not designed to compare equivalence statistically, it provides 
valuable data on switching from ETN to SB4 in patients with 
RA.
COnClusIOns
SB4 was well tolerated and effective over 2 years in patients 
with RA. Switching from ETN to SB4 was not associated with 
treatment-emergent issues such as loss of efficacy or increases 
in TEAEs or immunogenicity. Postmarketing surveillance and 
registry studies are ongoing to monitor the efficacy and safety 
of SB4 in various indications.
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